edotreotide has been researched along with dihydroxyphenylalanine in 2 studies
| Studies (edotreotide) | Trials (edotreotide) | Recent Studies (post-2010) (edotreotide) | Studies (dihydroxyphenylalanine) | Trials (dihydroxyphenylalanine) | Recent Studies (post-2010) (dihydroxyphenylalanine) |
|---|---|---|---|---|---|
| 206 | 34 | 86 | 8,823 | 322 | 833 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angelberger, P; Becherer, A; Dudczak, R; Karanikas, G; Kletter, K; Kurtaran, A; Raderer, M; Szabó, M; Wunderbaldinger, P | 1 |
| Balogova, S; Huchet, V; Kerrou, K; Michaud, L; Montravers, F; Nataf, V; Talbot, JN | 1 |
1 review(s) available for edotreotide and dihydroxyphenylalanine
| Article | Year |
|---|---|
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Topics: 3-Iodobenzylguanidine; Bronchial Neoplasms; Carcinoma, Merkel Cell; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung Neoplasms; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Recurrence; Sensitivity and Specificity; Thyroid Neoplasms; Tomography, Emission-Computed, Single-Photon | 2013 |
1 trial(s) available for edotreotide and dihydroxyphenylalanine
| Article | Year |
|---|---|
Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Topics: Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |